High Dose Somatostatin Analogues in Neuroendocrine Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2008

Conditions
Respiratory Tract NeoplasmsThymic NeoplasmsPancreatic NeoplasmsGastrointestinal NeoplasmsMultiple Endocrine Neoplasia
Interventions
DRUG

Octreotide-LAR

Octreotide-LAR 30 mg administered every 21 days until progression

Trial Locations (1)

80131

University Federico II of Naples, Naples

All Listed Sponsors
collaborator

University of Perugia, Faculty of Medicine, Department of Internal Medicine

OTHER

collaborator

University of Genova

OTHER

collaborator

University Hospital, Udine, Italy

OTHER

lead

Federico II University

OTHER

NCT00990535 - High Dose Somatostatin Analogues in Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter